Lack of correlation between epidermal growth factor receptor status and response to panitumumab monotherapy in metastatic colorectal cancer

Clinical Cancer Research

Volumn 16, Issue 7, 2010, Pages 2205-2213

  Hecht, J Randolph ^a   Mitchell, Edith ^b   Neubauer, Marcus A ^c   Burris III, Howard A ^d   Swanson, Paul ^f   Lopez, Timothy ^g   Buchanan, Glenn ^h   Reiner, Maureen ⁱ   Gansert, Jennifer ⁱ   Berlin, Jordan ^e  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b THOMAS JEFFERSON UNIVERSITY   (United States)

^c Kansas City Cancer Center   (United States)

^d Tennessee Oncology   (United States)

^e VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^f Hematology Oncology Associates of Treasure Coast   (United States)

^g New Mexico Cancer Care Associates   (United States)

^h Willamette Valley Cancer Center   (United States)

ⁱ AMGEN INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; PANITUMUMAB;

ACNEIFORM DERMATITIS; ADULT; AGED; ARTICLE; CANCER GROWTH; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; ERYTHEMA; FATIGUE; FEMALE; HUMAN; HYPOMAGNESEMIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; ONCOGENE K RAS; OVERALL SURVIVAL; PARONYCHIA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PRURITUS; SKIN FISSURE; SKIN TOXICITY; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA; COLORECTAL NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RECEPTOR, EPIDERMAL GROWTH FACTOR; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77950673501     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-09-2017     Document Type: Article

References (24)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249
2. Jost M, Kari C, Rodeck U. The EGF receptor - an essential regulator of multiple epidermal functions. Eur J Dermatol 2000;10:505-510
3. Gullick WJ. Prevalence of aberrant expression of the epidermal growth factor receptor in human cancers. Br Med Bull 1991;47:87-98.
4. Saltz LB, Meropol NJ, Loehrer PJ, Sr., Needle MN, Kopit J, Mayer RJ. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 2004;22:1201-1208
5. Cunningham D, Humblet Y, Siena S, et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 2004;351:337-345
6. Lenz HJ, Van Cutsem E, Khambata-Ford S, et al. Multicenter phase II and translational study of cetuximab in metastatic colorectal carcinoma refractory to irinotecan, oxaliplatin, and fluoropyrimidines. J Clin Oncol 2006;24:4914-4921
7. Van Cutsem E, Peeters M, Siena S, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007;25:1658-1664
8. Hecht JR, Patnaik A, Berlin J, et al. Panitumumab monotherapy in patients with previously treated metastatic colorectal cancer. Cancer 2007;110:980-988
9. Van Cutsem E, Siena S, Humblet Y, et al. An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy. Ann Oncol 2008;19:92-98
10. Kopp R, Rothbauer E, Ruge M, et al. Clinical implications of the EGF receptor/ligand system for tumor progression and survival in gastrointestinal carcinomas: evidence for new therapeutic options. Recent Results Cancer Res 2003;162:115-132
11. Vectibix® (panitumumab) prescribing information. Thousand Oaks, CA: Amgen Inc; 2006-2008.
12. Erbitux® (cetuximab) prescribing information. Branchburg, NJ: Imclone Systems Inc.; 2007.
13. Dei Tos AP. The biology of epidermal growth factor receptor and its value as a prognostic/predictive factor. Int J Biol Markers 2007;22:S3-9.
14. Amado RG, Wolf M, Peeters M, et al. Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 2008;26:1626-1634
15. Collett D. Modelling binary data. London: Chapman & Hall; 1991.
16. Brookmeyer R, Crowley J. A confidence interval for the median survival time. Biometrics 1982;38:29-41.
17. O'Neil BH, Allen R, Spigel DR, et al. High incidence of cetuximab-related infusion reactions in Tennessee and North Carolina and the association with atopic history. J Clin Oncol 2007;25:3644-3648
18. Chung KY, Shia J, Kemeny NE, et al. Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry. J Clin Oncol 2005;23:1803-1810
19. Mayer A, Takimoto M, Fritz E, Schellander G, Kofler K, Ludwig H. The prognostic significance of proliferating cell nuclear antigen, epidermal growth factor receptor, and mdr gene expression in colorectal cancer. Cancer 1993;71:2454-2460
20. Freeman DJ, Juan T, Reiner M, et al. Association of K-ras mutational status and clinical outcomes in patients with metastatic colorectal cancer receiving panitumumab alone. Clin Colorectal Cancer 2008;7:184-190
21. De Roock W, Piessevaux H, De Schutter J, et al. KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab. Ann Oncol 2008;19:508-515
22. Di Fiore F, Blanchard F, Charbonnier F, et al. Clinical relevance of KRAS mutation detection in metastatic colorectal cancer treated by Cetuximab plus chemotherapy. Br J Cancer 2007;96:1166-1169
23. Lievre A, Bachet JB, Le Corre D, et al. KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer. Cancer Res 2006;66:3992-3995
24. Lievre A, Bachet JB, Boige V, et al. KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab. J Clin Oncol 2008;26:374-379